Loading...
•
Mar 31, 2020
Verastem Q1 2020 Earnings Report
Presented promising activity of VS-6766 and Defactinib combination data in KRAS mutant solid tumors.
Key Takeaways
Verastem Oncology highlighted the potential of VS-6766 and Defactinib combination therapy, particularly in KRAS mutant cancers like LGSOC and NSCLC. Clinical data showed encouraging response rates and durability, especially in KRAS G12V variants. The company aims to initiate a registration-directed study in LGSOC in 2020 and expand cohorts in ongoing Phase 1 combination studies.
VS-6766 inhibits both MEK & RAF kinase activities, potentially enhancing therapeutic activity.
Defactinib, a selective FAK inhibitor, addresses resistance mechanisms activated by MEK inhibitors.
The combination of VS-6766 and defactinib demonstrated a 67% ORR in KRAS mutant LGSOC patients.
Clinical data showed promising results in heavily pre-treated refractory patients with KRAS mutant NSCLC.
Forward Guidance
Verastem Oncology is focused on advancing the clinical development of VS-6766 in combination with defactinib, particularly in LGSOC and KRAS G12V NSCLC. The company aims to initiate a registration-directed study in LGSOC in 2020 and complete expansion cohorts in ongoing Phase 1 combination studies. Verastem will also explore BRAFm-driven indications and combinations with KRAS-G12Ci and anti-PD-1 therapies.
Positive Outlook
- Initiate LGSOC registration-directed study in 2020
- Complete expansion cohorts in ongoing investigator initiated Phase 1 combination study
- Focus on KRAS - G12V & G12D expansion cohorts in NSCLC & pancreatic
- Explore BRAFm - driven indications
- Pursue combinations with KRAS - G12Ci & anti - PD - 1
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...